A. Benhammouda

640 total citations
22 papers, 437 citations indexed

About

A. Benhammouda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Benhammouda has authored 22 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in A. Benhammouda's work include Cancer Treatment and Pharmacology (7 papers), Immunotherapy and Immune Responses (5 papers) and Melanoma and MAPK Pathways (3 papers). A. Benhammouda is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Immunotherapy and Immune Responses (5 papers) and Melanoma and MAPK Pathways (3 papers). A. Benhammouda collaborates with scholars based in France, United States and Germany. A. Benhammouda's co-authors include D. Khayat, Olivier Rixe, E Antoine, Christian Borel, E. Vuillemin, L Thill, J.M. Tourani, Roger Mouawad, Thierry Dorval and Cornelis J.A. Punt and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Psycho-Oncology.

In The Last Decade

A. Benhammouda

21 papers receiving 425 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Benhammouda France 7 339 224 159 30 27 22 437
L. Orgiano Italy 8 226 0.7× 108 0.5× 180 1.1× 39 1.3× 34 1.3× 13 382
Stergios Moschos United States 12 532 1.6× 482 2.2× 297 1.9× 42 1.4× 22 0.8× 15 743
Anita Mohos Hungary 8 445 1.3× 461 2.1× 89 0.6× 24 0.8× 26 1.0× 11 559
Andy N. Tran United States 6 187 0.6× 156 0.7× 206 1.3× 45 1.5× 21 0.8× 6 360
Erika M. von Euw United States 7 228 0.7× 196 0.9× 221 1.4× 27 0.9× 57 2.1× 15 423
Gabriela Cinat Argentina 9 175 0.5× 115 0.5× 170 1.1× 21 0.7× 36 1.3× 20 318
Benjamin Weide Germany 13 328 1.0× 164 0.7× 246 1.5× 61 2.0× 62 2.3× 25 488
Nikolaus B. Wagner Germany 11 223 0.7× 139 0.6× 138 0.9× 49 1.6× 48 1.8× 22 340
Ragnar S. Faye Norway 10 218 0.6× 72 0.3× 191 1.2× 78 2.6× 58 2.1× 19 383
Margaret C. Sunderland United States 9 272 0.8× 136 0.6× 119 0.7× 76 2.5× 34 1.3× 11 420

Countries citing papers authored by A. Benhammouda

Since Specialization
Citations

This map shows the geographic impact of A. Benhammouda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Benhammouda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Benhammouda more than expected).

Fields of papers citing papers by A. Benhammouda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Benhammouda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Benhammouda. The network helps show where A. Benhammouda may publish in the future.

Co-authorship network of co-authors of A. Benhammouda

This figure shows the co-authorship network connecting the top 25 collaborators of A. Benhammouda. A scholar is included among the top collaborators of A. Benhammouda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Benhammouda. A. Benhammouda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Khayat, D., P. Chollet, Éric-Charles Antoine, et al.. (2001). Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer. Journal of Clinical Oncology. 19(14). 3367–3375. 15 indexed citations
4.
Khayat, D., et al.. (1998). European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.. PubMed. 12(8 Suppl 6). 64–7. 5 indexed citations
5.
Conradt, Christian, Sewa S. Legha, D. Khayat, et al.. (1998). Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.. Journal of Clinical Oncology. 16(9). 2921–2929. 160 indexed citations
6.
Rixe, Olivier, David Coeffic, B. Orcel, et al.. (1997). A Phase II Study of Cisplatin, 5-Fluorouracil, Leucovorin, and Etoposide in Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 20(2). 128–131. 1 indexed citations
7.
Coeffic, David, A. Benhammouda, O. Rixe, et al.. (1997). Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma.. PubMed. 24(1 Suppl 2). S2–38. 4 indexed citations
8.
Benhammouda, A., Anne Bernard, Nicole A. Mortier, et al.. (1997). Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.. PubMed. 3 Suppl 1. S16–21. 20 indexed citations
9.
10.
Mouawad, Roger, A. Benhammouda, Olivier Rixe, et al.. (1996). Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.. PubMed. 2(8). 1405–9. 61 indexed citations
11.
Rixe, Olivier, E. Vuillemin, A. Benhammouda, et al.. (1995). A Phase II Study of Tamoxifen Combined with Cisplatin-Interleukin 2 and Alpha-Interferon in Metastatic Melanoma. American Journal of Clinical Oncology. 18(5). 421–424. 6 indexed citations
12.
Rixe, Olivier, Christian Borel, D. Paraïso, et al.. (1995). Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma. Melanoma Research. 5(6). 419–424. 10 indexed citations
13.
Rixe, Olivier, A. Benhammouda, C Farabos, et al.. (1995). 955 A phase I study of concomitant CPT-11 (C) and 5FU (F) combination: Preliminary results. European Journal of Cancer. 31. S198–S199. 3 indexed citations
14.
Mouawad, Roger, Olivier Rixe, A. Benhammouda, et al.. (1994). Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clinical & Experimental Immunology. 97(3). 342–346. 6 indexed citations
15.
Smith, M. J., Roger Mouawad, E. Vuillemin, et al.. (1994). Psychological side effects induced by interleukin‐2/α interferon treatment. Psycho-Oncology. 3(4). 289–298. 4 indexed citations
16.
Rixe, Olivier, Bernard Maître, Thierry Petit, et al.. (1994). CDDP (P), 5FU (F), leucovorin (L) and VP16 (PFL-VP16) in advanced non small cell lung cancer (NSCLC). Lung Cancer. 11. 126–126. 1 indexed citations
17.
Khayat, D., Christian Borel, J.M. Tourani, et al.. (1993). Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.. Journal of Clinical Oncology. 11(11). 2173–2180. 116 indexed citations
18.
Khayat, D., E Antoine, Olivier Rixe, et al.. (1993). Chemoimmunotherapy of metastatic malignant melanoma The Salpétrière Hospital (SOMPS) experiences. European Journal of Cancer. 29. S2–S5. 6 indexed citations
19.
Khayat, D., E Antoine, Olivier Rixe, et al.. (1993). Interleukin2-alpha-interferon combined with cis-platyl therapy in metastatic malignant melanoma (MMM) patients: Results of two consecutive trials. European Journal of Cancer. 29. S179–S179. 1 indexed citations
20.
Khayat, D., A. Benhammouda, J.M. Tourani, et al.. (1993). Metastatic malignant melanoma (MMM). Melanoma Research. 3(1). 52–52. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Orgiano Breakdown of academic impact, for papers by Stergios Moschos Breakdown of academic impact, for papers by Anita Mohos Breakdown of academic impact, for papers by Andy N. Tran Breakdown of academic impact, for papers by Erika M. von Euw Breakdown of academic impact, for papers by Gabriela Cinat Breakdown of academic impact, for papers by Benjamin Weide Breakdown of academic impact, for papers by Nikolaus B. Wagner Breakdown of academic impact, for papers by Ragnar S. Faye Breakdown of academic impact, for papers by Margaret C. Sunderland
Rankless by CCL
2026